Company / Working Capital
AIM ImmunoTech Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
-$2.9M
FY2025
5-year range
-$5.4M / $49.5M
FY2021-FY2025
Trend
+45.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital returned to growth in FY2025 after 3 years of decline, reaching -$3M.
Based on SEC 10-K filings.
-$3M in FY2025.
Declined from $6M to -$3M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, working capital increased 45.3% year-over-year.
- Peak working capital was recorded in FY2021.
- Lowest working capital in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -71.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.9M | +45.3% |
| FY2024 | -$5.4M | -190.8% |
| FY2023 | $5.9M | -83.1% |
| FY2022 | $35.0M | -29.4% |
| FY2021 | $49.5M | +26.4% |
| FY2020 | $39.2M | +320.7% |
| FY2019 | $9.3M | +724.2% |
| FY2018 | -$1.5M | -287.1% |
| FY2017 | $798.0K | -82.3% |
| FY2016 | $4.5M | -44.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026